Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16409360 | 0.76 | CRHBP (0.38) | SLC6A4 | |
| SCHEMBL38665848 | 0.74 | SLC6A3 (0.48) | SLC6A3SLC6A4SLC6A2KDM4EMEN1 | |
| SCHEMBL19308438 | 0.71 | CHRM2 (0.55) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL1690206 | 0.71 | CHRM2 (0.55) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL16409291 | 0.67 | CHRM2 (0.51) | SLC6A3SLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL21590062 | 0.67 | SLC6A3 (0.56) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3158219 | 0.67 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2MAPK1 | |
| SCHEMBL16409282 | 0.66 | CHRM2 (0.47) | SLC6A3SLC6A2 | |
| SCHEMBL11742168 | 0.66 | SLC6A3 (0.42) | SLC6A3SLC6A4SLC6A2KDM4EMEN1 | |
| SCHEMBL10453624 | 0.66 | SLC6A3 (0.46) | SLC6A3SLC6A4SLC6A2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751875-B2 | Quinine compounds, and optical isomers, preparation method and medical use thereof | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2017-09-05 | — | — | US | disclosed |
| US-9751875-B2 | Quinine compounds, and optical isomers, preparation method and medical use thereof | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2017-09-05 | — | — | US | disclosed |
| US-20160244439-A1 | QUININE COMPOUNDS, AND OPTICAL ISOMERS, PREPARATION METHOD AND MEDICAL USE THEREOF | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| US-20160244439-A1 | QUININE COMPOUNDS, AND OPTICAL ISOMERS, PREPARATION METHOD AND MEDICAL USE THEREOF | BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| EP-3023424-A1 | QUININE COMPOUNDS, AND OPTICAL ISOMERS, PREPARATION METHOD AND MEDICAL USE THEREOF | Beijing Fswelcome Technology Development Co., Ltd (CN) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007073-A1 | QUININE COMPOUNDS, AND OPTICAL ISOMERS, PREPARATION METHOD AND MEDICAL USE THEREOF | 北京市丰硕维康技术开发有限责任公司 (CN) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244439-A1 | QUININE COMPOUNDS, AND OPTICAL ISOMERS, PREPARATION METHOD AND MEDICAL USE THEREOF | CHRM1, CHRM2, CHRM3 | SLC6A3 1379/4885SLC6A4 1550/4885SLC6A2 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.